Matthew J. O’Brien, MD, MSc

home / authors / matthew-j-o-brien-md-msc

Articles

December 12th 2023

Treatment Modification After Initiating Second-Line Medication for Type 2 Diabetes

David T. Liss, PhD Manisha Cherupally, MS Matthew J. O’Brien, MD, MSc Raymond H. Kang, MA Cassandra Aikman, MPH Amisha Wallia, MD, MS Andrew J. Cooper, MSc Eleena Koep, MS Emily D. Parker, PhD, MPH Ronald T. Ackermann, MD, MPH

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

March 9th 2021

Costs for Commercially Insured Adults Prescribed Second-line Diabetes Medications

David T. Liss, PhD Raymond H. Kang, MA Nicola Lancki, MPH Matthew J. O’Brien, MD, MSc Amisha Wallia, MD, MS Andrew J. Cooper, MSc Sterling A. Harris, BA Emily D. Parker, PhD, MPH Ronald T. Ackermann, MD, MPH

Adults with type 2 diabetes who received nonsulfonylurea medications had relative increases in total costs. Receiving newer medication classes led to relatively decreased medical costs.